Discontinuation report SANDOZ RIVASTIGMINE
| Report ID | 245279 |
| Drug Identification Number | 02324598 |
| Brand name | SANDOZ RIVASTIGMINE |
| Common or Proper name | RIVASTIGMINE |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | RIVASTIGMINE |
| Strength(s) | 4.5MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | 100HGC BO |
| ATC code | N06DA |
| ATC description | ANTI-DEMENTIA DRUGS |
| Reason for discontinuation | Manufacturing issues |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2024-12-10 |
| Remaining supply date | 2024-12-10 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2024-12-11 | English | Compare |
| v2 | 2024-12-10 | French | Compare |
| v1 | 2024-12-10 | English | Compare |
Showing 1 to 3 of 3